Skip to main content
. 2019 Aug 19;178(2):389–399. doi: 10.1007/s10549-019-05398-3

Table 6.

Kaplan–Meier estimates of 5-year EFS by pCR and PAM50 subtype in patients treated with trastuzumab-containing neoadjuvant regimens

pCR status PAM50 subtype No. of events/No. of patients 5-year EFS (%) (95% CI)
No pCR HERE 12/42 73.0 (56.6, 84.1)
Other 7/38 81.5 (65.1, 90.7)
pCR HER2E 8/86 90.1 (81.2, 94.9)
Other 2/10 80.0 (40.9, 94.6)

EFS event-free survival, HER2E HER2-enriched, PAM50 prediction analysis of microarray 50, pCR pathologic complete response in breast and nodes (ypN0/Tis ypN0)